X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 58 filers reported holding X4 PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 5.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,941,401 | -62.7% | 3,615,964 | -33.7% | 0.00% | -60.0% |
| Q2 2023 | $10,576,124 | +1125019.6% | 5,451,610 | +404.7% | 0.01% | +400.0% |
| Q1 2023 | $940 | -17.9% | 1,080,213 | -6.3% | 0.00% | 0.0% |
| Q4 2022 | $1,145 | -99.4% | 1,153,433 | +921.1% | 0.00% | – |
| Q3 2022 | $193,000 | +157.3% | 112,964 | +45.4% | 0.00% | – |
| Q2 2022 | $75,000 | -89.4% | 77,687 | -80.8% | 0.00% | – |
| Q1 2022 | $707,000 | +52.4% | 403,946 | +99.5% | 0.00% | – |
| Q4 2021 | $464,000 | -67.2% | 202,483 | -24.3% | 0.00% | -100.0% |
| Q3 2021 | $1,414,000 | -43.6% | 267,368 | -30.7% | 0.00% | -50.0% |
| Q2 2021 | $2,509,000 | +1420.6% | 386,007 | +2232.9% | 0.00% | – |
| Q1 2020 | $165,000 | -76.8% | 16,546 | -75.1% | 0.00% | -100.0% |
| Q4 2019 | $710,000 | -70.4% | 66,341 | -64.8% | 0.00% | -75.0% |
| Q3 2019 | $2,397,000 | +5.4% | 188,625 | +24.4% | 0.00% | +33.3% |
| Q2 2019 | $2,275,000 | – | 151,636 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 12,202,510 | $10,616 | 1.33% |
| Tri Locum Partners LP | 3,878,484 | $3,374,281 | 1.03% |
| Lynwood Capital Management Inc. | 900,000 | $783,000 | 0.71% |
| NEA Management Company, LLC | 11,736,793 | $10,211,010 | 0.71% |
| Parkman Healthcare Partners LLC | 2,797,147 | $2,433,518 | 0.53% |
| SCOGGIN MANAGEMENT LP | 484,796 | $567,025 | 0.33% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $291,450 | 0.24% |
| Ghost Tree Capital, LLC | 850,000 | $740,000 | 0.22% |
| Perceptive Advisors | 4,545,454 | $3,954,545 | 0.12% |
| Orbimed Advisors | 5,817,726 | $5,061,422 | 0.10% |